摘要
急性缺血性脑卒中(AIS)是指由于各种原因导致的脑组织局部供血不足所引起的神经功能性疾病,在AIS的治疗和二级预防中,利用抗血小板治疗是最常用的手段。替罗非班作为一种全新的抗血小板聚集药物,在心血管疾病应用中日渐成熟,但对于替罗非班在AIS静脉溶栓后的应用中仍存在一定争议。现将替罗非班在AIS静脉溶栓后的应用进展进行综述。
Acute ischemic stroke(AIS)is a neurological disorder caused by insufficient local blood supply to brain tissue due to various reasons.The application of antiplatelet therapy has reached a consensus in the treatment and secondary prevention of AIS.Tirofiban,a new antiplatelet aggregation drug,is becoming more and more mature in the application of cardiovascular diseases.However,there are still some disputes about the application of tirofiban after intravenous thrombolysis of AIS.This paper reviews the application progress of tirofiban after intravenous thrombolysis of AIS.
作者
谷飞
皮兴文
GU Fei;PI Xingwen(Hubei University of Traditional Chinese Medicine/Ezhou Hospital of Traditional Chinese Medicine,Ezhou 430000,China)
出处
《中国实用神经疾病杂志》
2021年第22期2017-2024,共8页
Chinese Journal of Practical Nervous Diseases
